Pure Global Cannabis Announces Letter of Intent for Pharmaceutical-Grade Cannabidiol With Isodial International

Published: August 2, 2018

Pure Global Cannabis Announces Letter of Intent for Pharmaceutical-Grade Cannabidiol With Isodial International

Pure Global Cannabis Inc., a vertically integrated growth-oriented life sciences has signed a letter of intent with Vancouver based Isodiol International Inc. for the ongoing supply of pharmaceutical and nutraceutical grade Cannabidiol (CBD) isolates, and other potential products.

Upon the successful importation and product testing of an initial trial order of raw CBD isolate, Pure Global and Isodiol intend to establish a Definitive Supply Agreement for the ongoing supply, of CBD isolate and intend to explore additional means of collaborating together.

“We’re excited to secure this pharmaceutical grade source of U.K. manufactured CBD from Isodiol at a time when new local British and regional European opportunities are presenting themselves by the day,” said Pure Global President & CEO, Malay Panchal. “Notwithstanding the growing demand for CBD in Canada and our plans for pharma and nutra grade imports, we call ourselves ‘Global’ for a reason. This is the first of a number of strategic initiatives which will help propel our international vision forward.”

As a GMP certified facility, Isodiol’s subsidiary BSPG Laboratories LTD. has received government approval from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of CBD under certificate number: UK API 48727.